Back to section
Investment in pharmaceutical sector
We have acted as Investor's legal advisors in relation to a US $ 18.5m investment in Lavipharm Corp., a subsidiary of, listed to Athens Exchange, Lavipharm S.A. The investment was effected through a convertible note, in order to enable Lavipharm to raise sufficient funds for the commercial launch of a transdermal fentanyl system in USA. A.S. Papadimitriou and Partners, acting as the Investor's legal advisors, advised also in relation to the conclusion of the agreements for the commercial launch of the above product, including the restructuring and settlement of Lavipharm's pending indebtedness and a new distribution agreement.